-
Mashup Score: 3CAR T and Bispecifics Take Center Stage in New Myeloma Trials - 18 day(s) ago
Adam D. Cohen, MD, discusses ongoing research influencing the multiple myeloma treatment landscape.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In an interview with Targeted Oncology, Doris Hansen, MD, delved into the background, methods, design, and results from 3 recent myeloma studies.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
During the morning session, the Committee will discuss supplemental biologics license application (sBLA) 125746.74 for CARVYKTI (ciltacabtagene autoleucel), …
Source: www.youtube.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 14ClinicalTrials.gov - 2 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: www.clinicaltrials.govCategories: General Medicine News, Partners & KOLsTweet-
Imp. article on "less is more" approaches in #myeloma. An ongoing "less is more" trial that I love is @AlGarfall's LimiTEC trial [https://t.co/VZqZFC1TjW], that will generate prospective data on fixed-duration [6-9 months] teclistamab. Glad to be a subsite for the trial! #mmsm https://t.co/PwibtI7DjM https://t.co/Q1qyBktWzK
-
-
Mashup Score: 7Advancing Myeloma Treatment With Blood-Based MRD Testing - 3 month(s) ago
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 32Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects - 3 month(s) ago
Myeloma is a common haematological malignancy in which adverse skeletal related events are frequently seen. Over recent years, treatment for myeloma has evolved leading to improved survival. Antiresorptive therapy is an important adjunct therapy to reduce the risk of bone fractures and to improve the quality of life for myeloma patients; however, this has the potential for unwanted side effects in the oral cavity and maxillofacial region. Osteonecrosis of the jaw related to antiresorptive medications and other myeloma therapies is not uncommon. This review serves to highlight the risk of osteonecrosis of the jaw for myeloma patients, with some suggestions for prevention and management.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
How I manage bone modifying agents (BMAs) in #myeloma to avoid jaw osteonecrosis: #mmsm - Obtain dental eval before starting BMAs - If pending invasive dental procedure, advise holding BMAs 2-3 months before and after - Dental exams every 6 months Ref: https://t.co/LDIpn3dvlF https://t.co/cpw2e8dj51
-
-
Mashup Score: 5
Abstract. Abstract 4079Background:. In multiple myeloma (MM), lenalidomide has impressive clinical activity in patients with both relapsed/refractory and newly
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12
Herbicide and pesticide exposure [e.g., agent orange (AO)] is associated with an increased risk of multiple myeloma (MM) due to the contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). However, it is unclear whether TCDD/AO exposure (AO exposure hereafter) …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US, and Naresh Bumma, The Ohio State University, Columbus, US. We asked, How to select maintenance therapies post-ASCT for patients with high-risk MM?
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1PERSEUS Supports D-VRd Followed by DR Maintenance as New SOC in MM - 5 month(s) ago
Paula Rodriguez-Otero, MD, PhD, discusses the promising results from the phase 3 PERSEUS trial in patients with newly diagnosed, transplant-eligible multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
WATCH: Adam D. Cohen, MD, discusses ongoing research influencing the multiple #myeloma treatment landscape. #MMSM | @PennMedicine https://t.co/bTmQCJ6u3a